GLP-1 Coverage and the New Medicare Bridge Program
By statute, Medicare Part D has long been barred from covering drugs prescribed for weight loss alone. That is why the same medication can be covered for one neighbor and not another: when a GLP-1 drug like Ozempic is prescribed for type 2 diabetes, it runs through your Part D plan under normal cost sharing rules, but the identical prescription written only for weight loss fell outside what Part D could pay. Two things soften that rule in 2026. First, Medicare covers obesity screening and behavioral counseling from a primary care provider at $0 for people with a body mass index of 30 or more. Second, a new Medicare program that started July 1, 2026 makes covered GLP-1 weight loss drugs available for a $50 monthly copayment to eligible beneficiaries with Part D coverage. Whether you qualify, and which drugs your plan includes, is exactly what we verify with your plan before you pay retail for anything.
Who qualifies for the $50 program, and what the $50 does not do
This program is only for people who already have Medicare drug coverage, including a standalone Medicare drug plan, a Medicare Advantage coordinated care plan with drug coverage, a Special Needs Plan, an employer or union group waiver plan, and the Limited Income Newly Eligible Transition program. If you are on Original Medicare with no drug plan at all, no BMI qualifies you, though Medicare does let you sign up for a drug plan at certain times, which would put this program back in reach. Even with that coverage, you are not eligible if you already get GLP-1 drugs through your Part D plan, or if you have type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease, though with those three diagnoses your Part D plan might still cover your GLP-1s. From there you must be 18 or older and meet one of three measurements when you start GLP-1 therapy: a BMI of 35 or higher; a BMI of 30 or higher with diastolic heart failure, uncontrolled high blood pressure, or chronic kidney disease at stage 3a or higher; or a BMI of 27 or higher with prediabetes, a previous heart attack or stroke, or peripheral artery disease with symptoms. The covered drugs are Foundayo tablets, Wegovy by injection or tablet, and Zepbound in the KwikPen only, not the single dose vials or pens. Once your prior authorization is approved it holds through December 31, 2027, refills and dose changes included, unless you change GLP-1s. The $50 does not count toward your yearly drug plan deductible or your yearly out of pocket limit, and it never appears on your Part D Explanation of Benefits. Does your own plan put you inside this program or outside it? Call Lara at (818) 472-5484 and find out.
What the 2026 rules actually cost you
The one figure Medicare.gov publishes for the new weight loss program is a $50 copayment for a monthly supply of covered GLP-1 drugs, available from July 1, 2026 for eligible beneficiaries with Part D coverage. Everything else depends on why the drug was prescribed, which the table below breaks down. Eligibility details for the new program come from your Part D plan, and we check them with you at no cost.
| Situation | What you pay |
|---|---|
| GLP-1 weight loss drugs through the new Medicare program that started July 1, 2026, if you are eligible and have Part D | $50 copayment for a monthly supply |
| Ozempic prescribed for type 2 diabetes through your Part D plan | Your plan's normal cost sharing, which counts toward the $2,100 Part D out of pocket cap in 2026 |
| Obesity screening and behavioral counseling from a primary care provider, for a BMI of 30 or more | $0 if your provider accepts assignment |
| A GLP-1 prescription written for weight loss alone, outside the new program | Full retail price, Part D cannot cover it |
Source: Medicare.gov, Obesity behavioral therapy coverage page, verified September 2026. The 2026 Part D out of pocket cap is $2,100.
Original Medicare vs Medicare Advantage
Since GLP-1 weight loss coverage runs through Part D drug benefits rather than Part B medical benefits, the distinction that matters most here is whether you have Part D drug coverage at all, whether through a standalone plan or through a Medicare Advantage plan that includes drug coverage. Medicare Advantage plans with drug coverage follow the same Part D rules for GLP-1 drugs, including eligibility for the new GLP-1 Bridge program and coverage for diabetes or cardiovascular indications. Some Medicare Advantage plans may have their own formulary placement and prior authorization steps for these drugs, so it is worth checking how your specific plan handles Ozempic, Wegovy, or similar medications before assuming coverage. If you are considering switching plans specifically to get better GLP-1 access, compare formularies carefully, since coverage for these drugs and any prior authorization steps can differ significantly even among Medicare Advantage plans offered in the same county.
Check Your GLP-1 Eligibility
Eligibility and paperwork for the GLP-1 Bridge run through your doctor and your Part D enrollment, so it helps to have a licensed agent confirm you are actually enrolled in Part D drug coverage before you pursue this. She can also check how your current plan handles GLP-1 drugs prescribed for diabetes or heart disease indications, and make sure you understand the BMI based criteria and prior authorization steps involved before your next enrollment window arrives. This kind of review is free, and it is available in English, Spanish, and Hebrew, so you can ask questions in whichever language is most comfortable for you. Before you call, it can help to have a recent Part D plan card or Medicare Advantage plan information on hand, along with any notes from your doctor about your BMI or related health conditions, since that can speed up the conversation. If you find you need to change your drug coverage to take advantage of these new rules, remember that most changes happen during the Annual Enrollment Period, which runs from October 15 to December 7, 2026. Call (818) 472-5484 to talk through your specific situation.
Call (818) 472-5484 to find out if you qualify for the new GLP-1 Bridge program.
Licensed in 11 states · 5.0 rated on Google · No cost to work with you